ERAS 주가 차트
ERAS 주가 예측
Erasca Inc
$15.05
-0.13%
$-0.01
종가: Jun 24, 16:00:00 GMT-4
$14.87
-1.17%
$-0.17
애프터마켓: Jun 24, 20:00:00 GMT-4
뒤로
Erasca Inc (ERAS) 주가 예측
주요 통계
이전 종가
$15.07
시가
$15.1
일일 범위
$14.65 - $15.34
52주 범위
$1.21 - $24.28
거래량
4.0M
평균 거래량
6.1M
배당수익률
--
EPS(TTM)
-0.93
시가총액
$4.6B
ERAS란 무엇인가요?
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
